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Introduction: The National Lung Screening Trial has ach-
ieved a 7% reduction in total mortality with low-dose
computed tomography (LDCT) screening as compared
with in the chest radiography arm. Other randomized trials
are under way, comparing LDCT screening with no inter-
vention. None of these studies was designed to investigate
the impact of smoking habits on screening outcome. In the
present study, we tested the effect of stopping smoking on
the overall mortality of participants undergoing repeated
LDCT screening for many years.
Methods: Between 2000 and 2010, 3381 smokers aged 50
years or older were enrolled in two LDCT screening
programs. On the basis of the last follow-up information,
subjects were divided into two groups: current smokers
throughout the screening period and former smokers.
Results: With a median follow-up time of 9.7 years and a
total of 32,857 person-years (PYs) of follow-up, a total of 151
deaths were observed in the group of 1797 current smokers
(17,846 PYs) versus 109 among 1584 former smokers
(15,011 PYs), corresponding to mortality rates of 8.46 and
7.26 for every 1000PYs, respectively. Comparedwith current
smokers, former smokers had an adjusted mortality hazard
ratio of 0.61 (95% conﬁdence interval: 0.44–0.83), with a
39% reduction in mortality. A similar reduction in mortalitywas observed in the subset of 712 late quitters, with a hazard
ratio of 0.65 (95% conﬁdence interval: 0.44–0.96).
Conclusions: Stopping smoking signiﬁcantly reduces the
overall mortality of smokers enrolled in LDCT screening
programs. The beneﬁcial effect of stopping smoking on total
mortality appears to be threefold to ﬁvefold greater than
the one achieved by earlier detection in the National Lung
Screening Trial.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Lung cancer kills 1.3 million people every year
worldwide,1 more than breast, colon, and prostate
cancer combined.2 In Western countries, lung cancer
mortality has constantly declined in men during the past
40 years, 20 years after a similar reduction in tobacco
consumption, whereas it is still rising in women from
several European countries, as well as in major devel-
oping countries such as China.3 The ﬁgures for lung
cancer represent a major determinant of the otherwise
moderate reduction in total cancer mortality observed
in the United States.2
According to the European Cancer Registry Based
Study on Survival and Care of Cancer Patients project, 5-
year survival after diagnosis of lung cancer has improved
in all European countries from 8% to 13% in the past
30 years.4–6 Despite expectations from therapeutic ad-
vances, however, the survival numbers remain dismal.7
Genuine hope for better lung cancer survival and
major reduction in mortality was generated by the use of
low-dose computed tomography (LDCT) for early
detection in heavy smokers.8,9 However, the present
evidence from randomized trials shows a reduction in
mortality of approximately 1% per year in the LDCT arm
of National Lung Screening Trial (NLST),10 but no beneﬁt
in the three smaller European studies with a pure
observational control arm.11–13 None of these studies
was designed to investigate the impact of smoking habits
on LDCT screening outcome.
Lung cancer accounts for less than one-third of overall
mortality in heavy smokers,14 and earlier detection, even if
minimally effective, cannot modify in a signiﬁcant manner
the risk proﬁle of screening participants who continue
to smoke.14 On the contrary, smoking cessation may
have a profound and rapid effect in these individuals.15
We considered the effect of smoking cessation on the
overall mortality of 3381 participants included from
2000 until 2015 in two prospective screening trials of
repeated annual or biennial LDCT.11,16Calendar year
2015
biennial LDCT yearly LDCT control
1,186 1,190 1,7231,005
3,381 participants 
included in the 
current study
follow-up
2010
Figure 1. Flow diagram of inclusion criteria in the current
study from previous pilot and Multicentric Italian Lung
Detection (MILD) trials. Thirty subjects from the pilot study
were randomized in the MILD trial after 5 years of screening.
LDCT, low-dose computed tomography.Methods
Study Population
The current study is based on two LDCT screening
programs launched in Milan since 2000. Details of these
screening programs have been reported elsewhere.11,16
Brieﬂy, the ﬁrst pilot trial started in 2000, offering
yearly LDCT for a minimum of 5 years to 1035 current
or former smokers who had a smoking history of at least
20 pack-years, were 50 years of age or older, and did
not report a history of cancer in the past 5 years.16 The
second trial, called Multicentric Italian Lung Detection
(MILD), started in 2005 and included 4099 smoker
participants with the same characteristics as in theprevious trial; 1723 were randomized to the control
group, 1190 to annual LDCT screening, and 1186 to
biennial LDCT screening.11 Thirty participants from the
pilot study were randomized in the MILD trial after 5
years of screening. Both studies included a smoking
cessation component for all subjects, with repeated
counseling at each screening clinic and speciﬁc advice
on different pharmacologic supports for those who
expressed a motivation for quitting. In the MILD cohort,
a group of 187 subjects who were persistent smokers
after 4 years of LDCT screening entered a smoking
cessation program with varenicline.17Cohort Selection
As shown in Figure 1, we included all 3381 smokers
aged 50 years or older who during the period from 2000
until 2010 received LDCT in the context of the two
Italian screening programs (i.e., the 1723 participants
who were randomized to the control group in the MILD
trial were excluded from the current study). The dy-
namic nature of inclusion in the cohort means that in-
dividuals contributed person-years (PYs) of observation
from the date of the ﬁrst screening visit (baseline) until
they were censored from further observation, either
because of death (from lung cancer or other causes) or
because they had reached the end of follow-up.Data Collection and Follow-Up
At the time of initial registration, as well as at each
annual or biennial clinical visit during the entire LDCT
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medical interview and a detailed self-administered
questionnaire. For the purpose of the present analysis,
an independent telephone interview focusing on late
smoking status and ﬁnal date of quitting was conducted
with all subjects with inconsistencies between ques-
tionnaires or missing information from the past 2 years.
On the basis of the last available information, all
participants were classiﬁed into two groups: current
smokers (i.e., patients who remained active smokers
throughout the LDCT screening period or stopped
smoking less than a year before the end of follow-up or
death) and former smokers otherwise. Former smokers
were further classiﬁed according to whether they
stopped smoking before baseline (early quitters) or
during follow-up (late quitters). Overall, two hierarchic
categorizations were used for the purpose of the current
study, the ﬁrst one including current and former
smokers and the second one dividing former smokers
into early and late quitters.
Life course smoking exposure of each participant was
measured at baseline and expressed by the cumulative
number of cigarettes smoked and the average number of
pack-years. Other baseline features included sex, age,
and lung function (percent predicted forced expiratory
volume in the ﬁrst second of expiration [FEV1]). Finally,
we recorded the date of detection of lung cancer during
follow-up.
Follow-up was closed on January 30, 2015, through
outpatient clinic, active telephone calls, and record
linkage with the vital status National Registry Ofﬁce
database. For deceased subjects, we obtained the death
certiﬁcate from the Italian Institute of Statistics. No pa-
tient was lost to follow-up: 3351 participants (99.1%)
were either dead or followed up for more than 5 years;
the median follow-up of the remaining 30 participants
was 55 months, with a minimum of 48 months.
Data Analysis
Descriptive statistics were used for summarizing the
baseline characteristics of the entire cohort as well as
those of the current and former smokers and early and
late quitters. The chi-square test, or its version for the
trend where appropriate, was used to test between-
group differences or trends.
Mortality rates were calculated from the observed
number of deaths and the corresponding PY experienced
by the cohort members. The 95% conﬁdence interval
(CI) was estimated under the assumption that the
number of deaths followed a Poisson distribution. Rates
were stratiﬁed according to smoking status, and
between-group differences were tested according to
normal approximation of the natural logarithm of rate
ratio. The overall mortality curves of current and formersmokers were calculated by the Kaplan-Meier estimator
and compared by the log-rank test.
The multivariable Cox proportional hazard regression
model was used to estimate the hazard ratio (HR) and
95% CI for predictors of time of death onset. The effect
of smoking status (i.e., the main predictor of interest)
was obtained by contrasting current and former
smokers, as well as current smokers and late and early
quitters. Adjustments were made for factors character-
izing patients at baseline, i.e., sex, age (quartile cate-
gories), FEV1 (100%, 80%–100%, and <80%), and
number of pack-years (20–39 and 40 or more). In
addition, because a diagnosis of lung cancer could affect
quitting behaviors,18 detection of lung cancer during
follow-up was considered. Because both smoking status
and cancer detection may vary over follow-up, assess-
ment of their value requires proper accounting for their
cumulative and varying nature. This was done by
including smoking and cancer detection as time-
dependent variables in the model.
The SAS statistical software package, version 9.4,
(SAS Institute, Cary, NC) was used for the analyses.
For all hypotheses tested, two-tailed p values less
than 0.05 or, in an equivalent manner, a 95% CI of the
HR that did not contain the value expected under the
null hypothesis (i.e., the value 1) were considered to be
signiﬁcant.
The ﬁrst pilot trial was approved by the institutional
review board and ethics committee in 2000,16 MILD trial
in 2005,11 and varenicline study in 2009 (European
Clinical Trials Database 2009-014301-14).17
Results
Smoking Features
In total, 3381 smokers enrolled in LDCT screening
programs were included in the current study. Fifty-three
percent of the cohort members (1797) were smokers
according to the last available (current) information.
Fifty-ﬁve percent of the former smokers had already
stopped smoking at baseline (872 early quitters),
whereas the remaining 45% stopped smoking during
follow-up (712 late quitters). Table 1 gives some
selected characteristics of participants according to their
smoking status. Sixty-nine percent were men, the median
age was 58 years, and the median smoking exposure was
40 pack-years. Women, participants younger than 54
years, and those who had smoked for more than 40
pack-years had a signiﬁcantly higher likelihood of being
current rather than former smokers.
Smoking Cessation and Mortality
Overall, 32,858 PYs were accumulated and 260
deaths occurred during follow-up, with a mortality rate
Table 1. Selected Features of the 3381 Individuals Included in the Study Cohort according to Their Smoking Status
Characteristic
Former Smokers, n (%)a
(n ¼ 1584)
Current Smokers, n (%)a
(n ¼ 1797)
Total, n (%)
(n ¼ 3381) p Valueb
Sex
Male 1200 (75.8) 1144 (63.7) 2344 (69.3) <0.0001
Female 384 (22.2) 653 (36.3) 1037 (30.7)
Age, y
<54 349 (22.0) 492 (27.4) 841 (24.9) 0.2812
54–58 370 (23.4) 466 (25.9) 836 (24.7)
58–62 385 (24.3) 429 (23.9) 814 (24.1)
62 480 (30.3) 410 (22.8) 890 (26.3)
Percentage predicted FEV1
100 684 (43.2) 701 (39.0) 1385 (41.0) 0.2007
80–100 642 (40.5) 822 (45.7) 1464 (43.3)
<80 258 (16.3) 274 (15.3) 532 (15.7)
Lung cancer detected during follow-up
No 1510 (95.3) 1732 (96.4) 3242 (95.9) 0.1233
Yes 74 (4.7) 65 (3.6) 139 (4.1)
Average no. pack-years
20–39 803 (50.7) 833 (46.4) 1636 (48.4) 0.0118
40 781 (49.3) 964 (53.6) 1745 (51.6)
aPatients who still smoked and those who had stopped smoking during the last screening visit were regarded as current and former smokers, respectively (see
the text for further speciﬁcations).
bThe p values refer to chi-square testing homogeneity of smoking status between strata (sex, lung cancer detection, and category of average no. pack-years) or
its trend over strata (age and FEV1).
FEV1, predicted forced expiratory volume in the ﬁrst second of expiration.
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Deaths due to lung cancer, other cancers, and other
causes, respectively, accounted for 28%, 34%, and 38%
of all deaths; 22%, 36%, and 42% of deaths in early
quitters; 29%, 39%, and 32% of deaths in late quitters;
and 30%, 32%, and 38% of deaths in current smokers.
Men and participants who had smoked for more than
40 PYs had a signiﬁcantly higher mortality rate than did
women and participants who had smoked less (Table 2).
As expected, a trend toward increased mortality rate
with increasing age and decreasing FEV1 was observed.
Although current smokers had a higher mortality
rate than did former smokers, the difference was not
signiﬁcant.
Figure 2 further shows that current smokers experi-
enced a higher mortality than did former smokers, with
corresponding overall mortality rates of 6.4% and 5.1%,
respectively. The difference, however, was of borderline
signiﬁcance (p ¼ 0.0503).
Figure 3 shows even stronger effects of smoking
cessation on mortality reduction by accounting for
covariates, including the time-dependent cancer detec-
tion rate and smoking habits during follow-up. Of in-
terest, both early and late quitters had signiﬁcantly
reduced mortality with respect to current smokers. Over
a median follow-up period of 9 years (minimum of 48
months), compared with current smokers, former
smokers had a reduction in mortality of 3% to 5% peryear. According to the multivariable Cox model, other
than smoking cessation, factors affecting mortality were
male sex (HR ¼ 1.56, 95% CI: 1.08–2.26), age older than
62 years (HR ¼ 3.18, 95% CI: 1.92–5.26), FEV1 lower
than 80% (HR ¼ 2.32; 95% CI: 1.55–3.47), and lung
cancer diagnosis during follow-up (HR ¼ 13.69; 95%
CI: 9.55–19.63).
Discussion
Large cohort studies based on hundreds of thousands
of individuals have demonstrated a two to three times
higher mortality due to all causes in lifelong smokers
compared with in never-smokers, with more than two-
thirds of all deaths that occurred in individuals aged
55 to 74 years being associated with smoking.19 Time
trends in the past 50 years showed a dramatic increase
in rates of death from chronic obstructive pulmonary
disease in male and female smokers and a signiﬁcant
decrease in never-smokers.19 Marked differences in
overall mortality according to smoking status (current,
former, or never) have been clearly shown in the British
Physician Cohort study.20 New studies have revealed
that a portion of the excess mortality in current smokers
is attributable to previously unestablished causes, such
as renal failure, hypertension, or infections.14 These
studies prove that even quitting smoking at an older age
(60 years) dramatically reduces mortality due to all
causes.15,19
Table 2. Observed Number of Deaths and Mortality Rates
for Every 1000 Person-Years according to Selected
Characteristics of Participants for their Effect on Mortality
Rate
Characteristic
No.
Deaths (PYs) MR (95% CI)
p
Valuea
Sex
Female 50 (10,095) 4.95 (3.58–6.32) <0.0001
Male 210 (22,763) 9.23 (7.98–10.47)
Age, y
<54 31 (8062) 3.85 (2.49–5.20) <0.0001
54–58 34 (8428) 4.03 (2.68–5.39)
58–62 59 (7993) 7.38 (5.50–9.27)
62 136 (8376) 16.24 (13.51–18.97)
Percentage predicted FEV1
100 57 (12,862) 4.43 (3.28–5.58) <0.0001
80–100 118 (14,751) 8.00 (6.56–9.44)
<80 85 (5246) 16.21 (12.76–19.65)
Average no. pack-years
<40 75 (15,686) 4.78 (3.70–5.86) <0.0001
40 185 (17,172) 10.77 (9.22–12.33)
Lung cancer detected during follow-up
No 204 (31,683) 6.44 (5.56–7.32) <0.0001
Yes 56 (1175) 47.66 (35.18–60.14)
Smoking statusb
Current smokers 151 (17,846) 8.46 (7.11–9.81) 0.2235
Former smokers 109 (15,012) 7.26 (5.89–8.62)
aThe p values refer to comparison between strata-speciﬁc mortality rates or
version for the trend when proper (age and FEV1).
bPatients who still smoked and those who had stopped smoking during the
last screening visit were regarded as current and former smokers, respec-
tively. Former smokers who stopped smoking before baseline and during
follow-up were regarded as late and early quitters, respectively.
PYs, person-years; MR, mortality rate; CI, conﬁdence interval; FEV1, pre-
dicted forced expiratory volume in the ﬁrst second of expiration.
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Figure 2. Kaplan-Meier overall mortality experienced by
current and former smokers. Patients who still smoked and
those who had stopped smoking during the last screening visit
were regarded as current and former smokers, respectively.
Figure 3. Effect of smoking cessation on overall mortality.
Hazard ratios (Cox model) and corresponding 95% conﬁdence
intervals estimating the effect of smoking cessation on
mortality. Estimates are adjusted for covariates measured at
baseline (sex, age, predicted forced expiratory volume in the
ﬁrst second of expiration, and average number of pack-years)
and during follow-up (lung cancer detection and smoking
status). HR, hazard ratio; CI, conﬁdence interval.
May 2016 Smoking and Mortality in LDCT Screening 697Although current U.S. guidelines emphasize the im-
portance of tobacco cessation treatment,21–23 in the past
decade the expectations for lung cancer screening with
LDCT have diverted the efforts from primary prevention
to early detection, particularly in heavy smokers. The
results of NLST showed that the absolute beneﬁt of LDCT
in this population is relatively modest (less than 1%
reduction in mortality per year), and the costs great. One
of the reasons for such a limited beneﬁt is the relative
weight of lung cancer in the overall mortality burden.14,19
In fact, the results of our study conﬁrm that lung cancer
accounts for less than 30% of all deaths in each of the
smoking subgroups. None of the ongoing trials on LDCT
screening was speciﬁcally designed to investigate the
impact of smoking habits on LDCT screening outcome.
The proportion of current smokers in the LDCT arm who
quit was 12% at 1 year among participants in the Danish
trial24 and 14% at 2 years in a sample of the Dutch-
Belgian Lung Cancer Screening Trial trial.25
The data reported here show that 28% of lifelong
current smokers who enter an LDCT screening program
with a median age of 57 years and smoking history of 40pack-years can stop smoking during screening interven-
tion as a consequence of counseling. However, the expe-
rience derived from a small subset of 187 subjects (7.9%)
from the MILD trial who were offered antitobacco ther-
apy with varenicline for 3 months revealed a carbon
monoxide–conﬁrmed quit rate of 49% at 3 months and
20% abstention at 12 months.17 These ﬁndings are
consistent with those of a recent study that was per-
formed in the context of the NLST trial and showed that
pharmacologic support delivered by a primary care pro-
vider is effective for smoking cessation.18 On the basis of
our ﬁndings, it is reasonable to estimate that systematic
treatment of all current smokers with varenicline within
the MILD trial, including repeated administration for a
ﬁrst failed attempt, might have signiﬁcantly improved
the proportion of ex-smokers at the end of the LDCT
screening program from the observed 53% to a cumu-
lative rate of 70% to 80%.
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programs for early detection of lung cancer corroborates
and expands evidence from previous investigations in
observational cohorts15 by showing that smoking
cessation is beneﬁcial in reducing mortality. Although
the difference between current and former smokers in
terms of mortality rate during follow-up was of bor-
derline signiﬁcance according to unadjusted analysis
(p ¼ 0.0503), signiﬁcant evidence of the beneﬁcial effect
of smoking cessation was observed after having adjusted
for lung cancer detection and the time-varying nature of
quitting smoking in a Cox proportional hazard model.
Of interest, the effect of smoking cessation during the
LDCT screening period was statistically signiﬁcant ac-
cording to the Cox multivariable model, with a 35%
reduction in mortality compared with that when smok-
ing was continued.
A recent study showed that the status of former
smoker at the time of enrollment in the NLST trial is a
favorable prognostic factor, with corresponding all-cause
mortality reduced by approximately 45% versus in
current smokers (i.e., the same magnitude of reduction
in all-cause mortality among early quitters observed in
our study).26 The NLST-based study, however, assumed
that smoking status did not change during follow-up,
which may not always be true, as shown in our inves-
tigation. Our study clearly shows that there is still a large
potential beneﬁt of smoking cessation once individuals
enter a screening program.
Notwithstanding the limited pharmacologic antito-
bacco support in our LDCT trials, the overall reduction in
mortality in ex-smoker cohorts was 3% to 5% per year,
representing a threefold to ﬁvefold greater beneﬁt than
the one achieved by LDCT screening in the NLST trial.
These results suggest that smokers who are older than
50 years and undergoing LDCT screening provide the
opportunity to test the efﬁcacy of primary prevention
strategies with a prospective and randomized design.
In the next 2 years, the mature results of the Dutch-
Belgian Lung Cancer Screening Trial trial, as well as
pooled analysis of all European randomized LDCT trials,
will provide a better understanding of the real beneﬁt of
lung cancer screening, the most effective criteria for
selection of high-risk individuals, and the optimal diag-
nostic algorithms. Regardless of the results of LDCT
screening, it is reasonable to expect that public policies
on early detection will have to be combined with active
intervention in smoking-related mortality to improve
their cost-beneﬁt ratio. Although the ongoing studies will
demonstrate the efﬁcacy of blood-based biomarkers in
improving LDCT performance and deﬁning individuals
at higher biologic risk,27 current smokers undergoing
LDCT screening could be randomized to pharmacologicantitobacco therapy versus counseling only, with mini-
mal increase in the total costs.
We are facing a revolutionary change in the prospects
of molecular medicine, with unprecedented outcome
improvements in chronic diseases such as hepatitis C
and cancer and a more than proportional growth in drug
expenditures. To be able to sustain the costs of poten-
tially curative treatments for unpreventable diseases,
we must reduce the costs of palliative management of
preventable ones, such as metastatic lung cancer, if we
want to make molecular medicine affordable for our
aging populations. Smoking cessation can produce sig-
niﬁcant and meaningful survival beneﬁts in the context
of lung cancer screening, and pharmacologic antitobacco
intervention therefore becomes a fundamental priority
in public health strategies.
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